公开(公告)号：US20210145963A9

公开(公告)日：2021-05-20

申请号：US14783699

申请日：2014-05-15

申请人： THE GOVERNORS OF THE UNIVERSITY OF ALBERTA

发明人： Michael Houghton ,  Darren Hockman ,  John L. Law ,  Michael Logan ,  D. Lorne Tyrrell

IPC分类号： A61K39/29

摘要： The present disclosure provides immunogenic compositions comprising HCV E1, E2, or E1/E2 polypeptides from two or more different HCV genotypes. The present disclosure provides immunogenic compositions comprising HCV E2 or E1/E2 polypeptides from two or more different HCV genotypes. The immunogenic compositions are useful in carrying out methods of inducing an immune response to HCV. The present disclosure further provides methods of stimulating an immune response to HCV in an individual.

公开(公告)号：US20190224308A1

公开(公告)日：2019-07-25

申请号：US16374403

申请日：2019-04-03

申请人： The Governors of the University of Alberta

发明人： Michael Houghton ,  John L. Law ,  Michael Logan ,  Darren Hockman ,  Abdolamir Landi

IPC分类号： A61K39/29 ,  C12N15/861 ,  A61P31/14 ,  A61P37/04 ,  A61K39/12 ,  A61K39/295 ,  A61P31/04

摘要： The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.

公开(公告)号：US20160067332A1

公开(公告)日：2016-03-10

申请号：US14783699

申请日：2014-05-05

申请人： THE GOVERNORS OF THE UNIVERSITY OF ALBERTA

发明人： Michael Houghton ,  Darren Hockman ,  John L. Law ,  Michael Logan ,  D. Lorne Tyrrell

IPC分类号： A61K39/29

CPC分类号： A61K39/29 ,  A61K39/12 ,  A61K2039/70 ,  C12N2770/24234

摘要： The present disclosure provides immunogenic compositions comprising HCV E1, E2, or E1/E2 polypeptides from two or more different HCV genotypes. The present disclosure provides immunogenic compositions comprising HCV E2 or E1/E2 polypeptides from two or more different HCV genotypes. The immunogenic compositions are useful in carrying out methods of inducing an immune response to HCV. The present disclosure further provides methods of stimulating an immune response to HCV in an individual.

摘要翻译： 本公开提供包含来自两种或更多种不同HCV基因型的HCV E1，E2或E1 / E2多肽的免疫原性组合物。 本公开提供包含来自两种或更多种不同HCV基因型的HCV E2或E1 / E2多肽的免疫原性组合物。 免疫原性组合物可用于进行诱导对HCV的免疫应答的方法。 本公开进一步提供刺激个体对HCV的免疫应答的方法。

公开(公告)号：US20240316186A1

公开(公告)日：2024-09-26

申请号：US18520057

申请日：2023-11-27

申请人： The Governors of the University of Alberta

发明人： Michael Houghton ,  Darren Hockman ,  John L. Law ,  Michael Logan ,  D. Lorne Tyrrell

IPC分类号： A61K39/29 ,  A61K39/12

CPC分类号： A61K39/29 ,  A61K39/12 ,  C12N2770/24234

摘要： The present disclosure provides immunogenic compositions comprising HCV E1, E2, or E1/E2 polypeptides from two or more different HCV genotypes. The present disclosure provides immunogenic compositions comprising HCV E2 or E1/E2 polypeptides from two or more different HCV genotypes. The immunogenic compositions are useful in carrying out methods of inducing an immune response to HCV. The present disclosure further provides methods of stimulating an immune response to HCV in an individual.

公开(公告)号：US20230310590A1

公开(公告)日：2023-10-05

申请号：US18099044

申请日：2023-01-19

申请人： The Governors of the University of Alberta

发明人： Michael Houghton ,  John L. Law ,  Michael Logan ,  Darren Hockman ,  Abdolamir Landi

IPC分类号： A61K39/29 ,  A61K39/12 ,  A61P37/04 ,  A61P31/14 ,  A61P31/04 ,  A61K39/295 ,  C12N15/861

CPC分类号： A61K39/29 ,  A61K39/12 ,  A61P37/04 ,  A61P31/14 ,  A61P31/04 ,  A61K39/295 ,  C12N15/861 ,  C07K2319/00 ,  C12N2770/24234 ,  A61K2039/55544

摘要： The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.

公开(公告)号：US20230098265A1

公开(公告)日：2023-03-30

申请号：US17702231

申请日：2022-03-23

申请人： The Governors of the University of Alberta

发明人： Michael Houghton ,  Darren Hockman ,  John L. Law ,  Michael Logan ,  D. Lorne Tyrrell

IPC分类号： A61K39/29 ,  A61K39/12

摘要： The present disclosure provides immunogenic compositions comprising HCV E1, E2, or E1/E2 polypeptides from two or more different HCV genotypes. The present disclosure provides immunogenic compositions comprising HCV E2 or E1/E2 polypeptides from two or more different HCV genotypes. The immunogenic compositions are useful in carrying out methods of inducing an immune response to HCV. The present disclosure further provides methods of stimulating an immune response to HCV in an individual.

公开(公告)号：US12048742B2

公开(公告)日：2024-07-30

申请号：US16978486

申请日：2019-03-14

申请人： The Governors of the University of Alberta

发明人： Michael Houghton ,  Abdolamir Landi ,  Michael Logan ,  John L. Law ,  Chao Chen ,  Darren Hockman

IPC分类号： A61K39/29 ,  A61K39/00 ,  A61P31/14 ,  A61P37/04

CPC分类号： A61K39/29 ,  A61P31/14 ,  A61P37/04 ,  A61K2039/55505 ,  C12N2770/24222 ,  C12N2770/24234

摘要： The present disclosure provides an immunogenic composition comprising: a) i) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; ii) an HCV E1 polypeptide; or iii) an HCV E2 polypeptide; b) a polypeptide (also referred to herein as a “T-cell epitope polypeptide” or an “HCV T-cell epitope polypeptide”) comprising T-cell epitopes (e.g., CD4+ and CD8+ T-cell epitopes that are conserved among some HCV genotypes and that are presented through one or multiple HLA alleles common within the human population) present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide.

公开(公告)号：US20210100895A1

公开(公告)日：2021-04-08

申请号：US17122578

申请日：2020-12-15

申请人： The Governors of the University of Alberta

发明人： Michael Houghton ,  John L. Law ,  Michael Logan ,  Darren Hockman ,  Abdolamir Landi

IPC分类号： A61K39/29 ,  A61K39/12 ,  A61P37/04 ,  A61P31/14 ,  A61P31/04 ,  A61K39/295 ,  C12N15/861

摘要： The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.

公开(公告)号：US20190209677A1

公开(公告)日：2019-07-11

申请号：US16334683

申请日：2017-09-21

申请人： The Governors of the University of Alberta

发明人： Michael Houghton ,  Abdolamir Landi ,  Michael Logan ,  John L. Law ,  Darren Hockman ,  Chao Chen

IPC分类号： A61K39/29

CPC分类号： A61K39/29 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/55544 ,  A61K2039/70 ,  C12N2710/10034 ,  C12N2710/10043 ,  C12N2710/24134 ,  C12N2710/24143 ,  C12N2770/24234

摘要： The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient.

公开(公告)号：US20180282377A1

公开(公告)日：2018-10-04

申请号：US15763370

申请日：2016-10-07

申请人： The Governors of the University of Alberta

发明人： Michael Houghton ,  Darren Hockman ,  John L. Law ,  Chao Chen ,  Michael Logan

IPC分类号： C07K14/005 ,  C12N7/00 ,  A61K39/29

摘要： The present disclosure provides affinity tagged heterodimeric polypeptides comprising a hepatitis C virus (HCV) E1 polypeptide and an HCV E2 polypeptide, where one or both of the E1 and E2 polypeptides comprises an affinity tag. The present disclosure provides a method of producing an affinity tagged E1/E2 heterodimer of the present disclosure. The present disclosure provides methods of producing untagged HCV E1/E2 heterodimers. The present disclosure provides HCV E1/E2 heterodimers, compositions comprising same, and methods of inducing an immune response to HCV.